Stimulus properties of venlafaxine in a conditioned taste aversion procedure
No Thumbnail Available
Date
2008-10-31
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Conditioned stimulus properties of venlafaxine are still unknown. In the present study, the discriminative stimulus properties of venlafaxine by using a conditioned taste aversion procedure were investigated. Swiss Webster mice were allowed to reach water from 2 pipettes for 20 min (09:00-11:30 h), plus 30 min (15:3016:00 h), daily. During the 4 days, the test drugs [fluoxetine, escitalopram, tianeptine, reboxetine, and N omega-nitro-L-arginine methyl ester(L-NAME)l were injected to mice at least 1 h after they had first water session. On day 5, they consumed glucose solution(5%w/v) and immediately injected with conditioning drug (venlafaxine 32 mg/kg). On day 8, mice were allowed to make a choice between water and glucose solution. The amount of glucose consumption as a percentage of total fluid intakes was calculated for each animal. Significant reduction in glucose choice was defined as conditioned taste aversion. Venlafaxine (32 mg/kg) induced a robust conditioned taste aversion in mice. Pre-exposure to tianeptine (2.5-10 mg/kg), fluoxetine (10 mg/kg), escitalopram (32 mg/kg), and reboxetine (5 mg/kg) substituted for venlafaxine by preventing the conditioned taste aversion induced by venlafaxine. L-NAME did not substitute for venlafaxine. Substitution of venlafaxine by fluoxetine, tianeptine, escitalopram, and reboxetine provides further evidence that both 5-HT and noradrenaline reuptake inhibition may play an important role in the stimulus effect of venlafaxine.
Description
Keywords
(Mice), Antidepressant, Conditioned taste aversion, Escitalopram, Fluoxetine, I- name, Reboxetine, Tianeptine, Venlafaxine, Serotonin reuptake inhibitor, Discriminative stimulus, Antidepressant, Citalopram, Drugs, Pharmacology & pharmacy
Citation
Kayır, H. vd. (2008). "Stimulus properties of venlafaxine in a conditioned taste aversion procedure". European Journal of Pharmacology, 596(1-3), 102-106.